- Home
- PMVP vs KRRO Comparison
PMVP vs KRRO Comparison
Compare PMVP & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMVP | KRRO |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.0M | 58.6M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PMVP | KRRO |
|---|---|---|
| Price | $1.20 | $8.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $5.00 | ★ $74.17 |
| AVG Volume (30 Days) | ★ 217.0K | 216.8K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,371,000.00 |
| Revenue This Year | N/A | $144.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.81 | $5.20 |
| 52 Week High | $1.84 | $55.89 |
Technical Indicators
Market Signals| Indicator | PMVP | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 45.34 |
| Support Level | $1.20 | $7.82 |
| Resistance Level | $1.26 | $8.14 |
| Average True Range (ATR) | 0.05 | 0.47 |
| MACD | 0.00 | 0.67 |
| Stochastic Oscillator | 44.38 | 97.17 |
Price Performance
Historical ComparisonAbout PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.